RosalynGeorgeMD

Dermatology • Wilmington, NC

Physician

Join to view full profile

Dr. George is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. George's full profile

Already have an account?

Office
710 Military Cutoff Rd
Suite 320
Wilmington, NC 28405
Phone+1 910-256-4350

Fax+1 910-239-5032

Education & Training

Penn State Milton S Hershey Medical CenterResidency, Dermatology, 2005 - 2008
Penn State Milton S Hershey Medical CenterInternship, Internal Medicine, 2004 - 2005
Virginia Commonwealth University School of MedicineClass of 2004

Certifications & Licensure

NC State Medical License 2008 - 2025
MD State Medical License 2016 - 2016
PA State Medical License 2004 - 2008
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
Fellow (FAAD) American Academy of Dermatology

Clinical Trials

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis Start of enrollment: 2015 Aug 01
Completed
Phase 3
Simulines Non-Inferiority Pivotal Study Start of enrollment: 2016 Apr 11
Terminated
Not Applicable
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis Start of enrollment: 2019 Aug 12
Active, not recruiting
Phase 3
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis Start of enrollment: 2019 Oct 29
Completed
Phase 3
Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. Start of enrollment: 2020 Feb 03
Completed
Phase 3
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) Start of enrollment: 2020 Jun 15
ACTIVE_NOT_RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

1 citations
Improvement of platysma prominence with onabotulinumtoxinA: Safety and efficacy results from a randomized, double-blinded, placebo-controlled phase 3 trial.
Sabrina Fabi, Shannon Humphrey, Brian Biesman, Rosalyn George, Brenda LaTowsky
Journal of the American Academy of Dermatology. 2025-02-01
1 citations
Efficacy and Safety of RelabotulinumtoxinA, a New Ready-to-Use Liquid Formulation Botulinum Toxin: Results From the READY-1 Double-Blind, Randomized, Placebo-Controlle...
Sachin M Shridharani, Amir Moradi, Lisa Donofrio, Michael H Gold, Brian Biesman
Aesthetic Surgery Journal. 2024-11-15
7 citations
A Randomized Trial to Assess Effectiveness and Safety of a Hyaluronic Acid Filler for Chin Augmentation and Correction of Chin Retrusion.
Keith Marcus, Amir Moradi, Joely Kaufman-Janette, Glynis Ablon, Lisa Donofrio
Plastic and Reconstructive Surgery. 2022-12-01

Press Mentions

Evaluation of the Safety and Efficacy of Microfocused Ultrasound with Visualization (MFU-V) for the Treatment of Signs and Symptoms of Erythematotelangiectatic Rosacea: Final DataJune 9th, 2017
Merz Aesthetics Announces Two Late-Breaking Research Forum Presentations at the American Academy of Dermatology MeetingMarch 4th, 2016
Workout Facials: Can Exercising Your Face Really Make It Look Younger?December 1st, 2015
Join now to see all

Professional Memberships

American Academy of Dermatology - AAD
Fellow